These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 9765314

  • 1. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
    Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU.
    J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
    Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S.
    Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
    [Abstract] [Full Text] [Related]

  • 4. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.
    Sutherland MK, Brady H, Gayo-Fung LM, Leisten J, Lipps SG, McKie JA, O'Leary E, Patnaik N, Anderson DW, Bhagwat SS, Stein B.
    Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000
    [Abstract] [Full Text] [Related]

  • 5. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
    Armamento-Villareal R, Sheikh S, Nawaz A, Napoli N, Mueller C, Halstead LR, Brodt MD, Silva MJ, Galbiati E, Caruso PL, Civelli M, Civitelli R.
    J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
    [Abstract] [Full Text] [Related]

  • 6. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
    Sato M, McClintock C, Kim J, Turner CH, Bryant HU, Magee D, Slemenda CW.
    J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
    [Abstract] [Full Text] [Related]

  • 7. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
    Sato M, Rippy MK, Bryant HU.
    FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
    [Abstract] [Full Text] [Related]

  • 8. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
    Sato M, Bryant HU, Iversen P, Helterbrand J, Smietana F, Bemis K, Higgs R, Turner CH, Owan I, Takano Y, Burr DB.
    J Pharmacol Exp Ther; 1996 Oct; 279(1):298-305. PubMed ID: 8859007
    [Abstract] [Full Text] [Related]

  • 9. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
    Nuttall ME, Bradbeer JN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H, Rehm S, Gowen M.
    Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
    Galbiati E, Caruso PL, Amari G, Armani E, Ghirardi S, Delcanale M, Civelli M.
    J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
    [Abstract] [Full Text] [Related]

  • 11. The effects of raloxifene on tibia histomorphometry in ovariectomized rats.
    Evans G, Bryant HU, Magee D, Sato M, Turner RT.
    Endocrinology; 1994 May; 134(5):2283-8. PubMed ID: 8156931
    [Abstract] [Full Text] [Related]

  • 12. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
    Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR.
    J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
    [Abstract] [Full Text] [Related]

  • 13. Effects of 3-phenyl-4-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]- 2H-1-benzopyran-7-ol (CHF 4056), a novel nonsteroidal estrogen agonist/antagonist, on reproductive and nonreproductive tissue.
    Galbiati E, Caruso PL, Amari G, Armani E, Ghirardi S, Delcanale M, Civelli M.
    J Pharmacol Exp Ther; 2002 Mar; 300(3):802-9. PubMed ID: 11861784
    [Abstract] [Full Text] [Related]

  • 14. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
    Ke HZ, Chen HK, Qi H, Pirie CM, Simmons HA, Ma YF, Jee WS, Thompson DD.
    Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
    [Abstract] [Full Text] [Related]

  • 15. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
    Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P, Thompson DD.
    Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
    [Abstract] [Full Text] [Related]

  • 16. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
    Qu Q, Zheng H, Dahllund J, Laine A, Cockcroft N, Peng Z, Koskinen M, Hemminki K, Kangas L, Väänänen K, Härkönen P.
    Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
    [Abstract] [Full Text] [Related]

  • 17. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
    Grese TA, Cho S, Finley DR, Godfrey AG, Jones CD, Lugar CW, Martin MJ, Matsumoto K, Pennington LD, Winter MA, Adrian MD, Cole HW, Magee DE, Phillips DL, Rowley ER, Short LL, Glasebrook AL, Bryant HU.
    J Med Chem; 1997 Jan 17; 40(2):146-67. PubMed ID: 9003514
    [Abstract] [Full Text] [Related]

  • 18. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
    Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, Chidsey-Frink KL, Ma YF, Jee WS, Thompson DD.
    Bone; 1997 Jan 17; 20(1):31-9. PubMed ID: 8988345
    [Abstract] [Full Text] [Related]

  • 19. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
    Sato M, Kim J, Short LL, Slemenda CW, Bryant HU.
    J Pharmacol Exp Ther; 1995 Mar 17; 272(3):1252-9. PubMed ID: 7891341
    [Abstract] [Full Text] [Related]

  • 20. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
    Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD.
    Endocrinology; 1995 Jun 17; 136(6):2435-41. PubMed ID: 7750465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.